RadNet‘s wholly-owned subsidiary DeepHealth has completed its acquisition of iCAD, a provider of AI-powered breast health solutions. The deal integrates iCAD’s commercial, technology, and regulatory capabilities into DeepHealth’s digital health platform focused on cancer screening and diagnosis.
iCAD’s AI portfolio includes breast cancer detection, risk evaluation, breast density assessment, and breast arterial calcification analysis. The technology is deployed across more than 50 countries and serves over 1,500 healthcare provider locations worldwide.
The acquisition expands DeepHealth’s market reach to over 10 million mammograms annually and aims to accelerate AI adoption in breast cancer screening programs globally. iCAD’s extensive installed base provides DeepHealth with access to communities that may be underserved by current screening technologies.
“We are excited to welcome the iCAD team to DeepHealth,” said Kees Wesdorp, President and CEO of RadNet’s Digital Health segment. “The integration of iCAD further empowers DeepHealth to meet the real-world clinical needs of today, from improving the accuracy and early detection of breast cancer to orchestrating large-scale screening programs.”
DeepHealth operates as the umbrella brand for RadNet’s digital health companies, including previously acquired AI firms Aidence, Kheiron, Quantib, and See-Mode. The platform provides AI-powered solutions for lung, breast, prostate, and brain health through its cloud-native DeepHealth OS operating system.
The combined portfolio integrates complementary technologies and datasets to enhance AI model performance across cancer screening and detection pathways. DeepHealth aims to improve both cancer detection rates and workflow efficiency through the unified platform.
RadNet operates 401 outpatient imaging centers across multiple U.S. states and employs over 11,000 people including contracted radiologists, employees, and technologists.
